Chapter 64

S.B. No. 172

AN ACT
relating to the addition of certain substances to Penalty Groups 1-A and 2 of the Texas Controlled Substances Act for criminal prosecution and other purposes.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. Section 481.002(50), Health and Safety Code, is amended to read as follows:

(50) "Abuse unit" means:
(A) except as provided by Paragraph (B):
   (i) a single unit on or in any adulterant, dilutant, or similar carrier medium, including marked or perforated blotter paper, a tablet, gelatin wafer, sugar cube, or stamp, or other medium that contains any amount of a controlled substance listed in Penalty Group 1-A, if the unit is commonly used in abuse of that substance; or
   (ii) each quarter-inch square section of paper, if the adulterant, dilutant, or carrier medium is paper not marked or perforated into individual abuse units; or
   (B) if the controlled substance is in liquid or solid form, 40 micrograms of the controlled substance including any adulterant or dilutant.

SECTION 2. Section 481.1021, Health and Safety Code, is amended to read as follows:

Sec. 481.1021. PENALTY GROUP 1-A. (a) Penalty Group 1-A
S.B. No. 172

consists of:

(1) lysergic acid diethylamide (LSD), including its salts, isomers, and salts of isomers; and

(2) compounds structurally derived from 2,5-dimethoxyphenethylamine by substitution at the 1-amino nitrogen atom with a benzyl substituent, including:

(A) compounds further modified by:

(i) substitution in the phenethylamine ring at the 4-position to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents); or

(ii) substitution in the benzyl ring to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents); and

(B) by example, compounds such as:

4-Bromo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25B-NBOMe, 2C-B-NBOMe);

4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25C-NBOMe, 2C-C-NBOMe);

2,5-Dimethoxy-4-methyl-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25D-NBOMe, 2C-D-NBOMe);

4-Ethyl-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25E-NBOMe, 2C-E-NBOMe);

2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (some trade and other names: 25H-NBOMe, 2C-H-NBOMe);

4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (some trade and other names: 25I-NBOMe,
S.B. No. 172

2C-I-NBOMe); 4-Iodo-2,5-dimethoxy-N-
benzylphenethylamine (trade or other name: 25I-NB); 4-Iodo-2,5-dimethoxy-N-(2,3-
methyleneedioxybenzyl)phenethylamine (trade or other name: 25I-NBMD); 4-Iodo-2,5-dimethoxy-N-(2-
fluorobenzyl)phenethylamine (trade or other name: 25I-NBF); 4-Iodo-2,5-dimethoxy-N-(2-hydroxybenzyl)
phenethylamine (trade or other name: 25I-NBOH); 2,5-Dimethoxy-4-nitro-N-(2-methoxybenzyl)
phenethylamine (trade or other name: 25N-NBOMe, 2C-N-NBOMe); and 2,5-Dimethoxy-4-(n)-propyl-N-(2-
methoxybenzyl)phenethylamine (some trade and other names: 25P-NBOMe, 2C-P-NBOMe).

(b) To the extent Subsection (a)(2) conflicts with another provision of this subtitle or another law, the other provision or the other law prevails.

SECTION 3. Section 481.103, Health and Safety Code, is amended by amending Subsections (a) and (c) and adding Subsection (d) to read as follows:

(a) Penalty Group 2 consists of:

(1) any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, if the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
S.B. No. 172

5-(2-aminopropyl)benzofuran (5-APB);
6-(2-aminopropyl)benzofuran (6-APB);
5-(2-aminopropyl)-2,3-dihydrobenzofuran
(5-APDB);
6-(2-aminopropyl)-2,3-dihydrobenzofuran
(6-APDB);
5-(2-aminopropyl)indole (5-IT, 5-API);
6-(2-aminopropyl)indole (6-IT, 6-API);
1-(benzofuran-5-yl)-N-methylpropan-2-amine
(5-MAPB);
1-(benzofuran-6-yl)-N-methylpropan-2-amine
(6-MAPB);
Benzothiophenylcyclohexylpiperidine (BTCP);
8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran-
4-ethanamine (trade or other name: Bromo-DragonFLY);
Desoxyxipradrol (2-benzhydrylpiperidine);
[alpha-ethyltryptamine,]
[alpha-methyltryptamine,]
[4-bromo-2, 5-dimethoxyamphetamine (some trade or
other names: 4-bromo-2, 5-dimethoxy-alpha-methylphenethylamine,]
[4-bromo-2, 5-DMA)];
[4-bromo-2, 5-dimethoxyphenethylamine,]
[Bufotenine (some trade and other
names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole,]
[3-(2-dimethylaminoethyl)-5-indolol, N, N-dimethylserotonin,]
[5-hydroxy-N, N-dimethyltryptamine, mappine,]
[Diethyltryptamine (some trade and other
names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole,]
S.B. No. 172

names: N, N-Diethyltryptamine, DET);

2, 5-dimethoxyamphetamine (some trade or other
names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA);
Diphenylprolinol (diphenyl(pyrrolidin-2-yl)
methanol, D2PM);

[2, 5-dimethoxy-4-ethylamphetamine (trade or
other name: DOET),]

[2, 5-dimethoxy-4-(n)-propylthiophenethylamine
(trade or other name: 2C-T-7),]

Dimethyltryptamine (trade or other name: DMT),
Dronabinol (synthetic) in sesame oil and
encapsulated in a soft gelatin capsule in a U.S. Food and Drug
Administration approved drug product (some trade or other names for
Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro-
6,6, 9-
trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol or (-)-delta-9-
(trans)-tetrahydrocannabinol);
Ethylamine Analog of Phencyclidine (some trade or
other names: N-ethyl-1-phenylcyclohexylamine, (1-
phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine,
cyclohexamine, PCE);
2-ethylamino-2-(3-methoxyphenyl)cyclohexanone
(trade or other name: methoxetamine);

Ibogaine (some trade or other names: 7-Ethyl-6,
6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-
pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.);
5-iodo-2-aminoindane (5-IAI);
Mescaline;
S.B. No. 172

1 [5-methoxy-N,N-diisopropyltryptamine;]
2 5-methoxy-3, 4-methylenedioxy amphetamine;
3 4-methoxyamphetamine (some trade or other
4 names: 4-methoxy-alpha-methylphenethylamine;
5 paramethoxyamphetamine; PMA);
6 4-methoxymethylamphetamine (PMMA);
7 2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone
8 (some trade and other names: 2-MeO-ketamine; methoxyketamine);
9 1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP,
10 PPMP);
11 4-methyl-2, 5-dimethoxyamphetamine (some trade
12 and other names: 4-methyl-2, 5-dimethoxy-alpha-
13 methylphenethylamine; "DOM"; "STP");
14 3,4-methylenedioxy methylamphetamine (MDMA, MDM);
15 3,4-methylenedioxy amphetamine;
16 3,4-methylenedioxy N-ethylamphetamine (Also
17 known as N-ethyl MDA);
18 5,6-methylenedioxy-2-aminooindane (MDAI);
19 Nabilone (Another name for nabilone: (+)-trans-
20 3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6,
21 6-dimethyl-9H-dibenzo[b,d] pyran-9-one;
22 N-benzylpiperazine (some trade or other
23 names: BZP; 1-benzylpiperazine);
24 N-ethyl-3-piperidyl benzilate;
25 N-hydroxy-3,4-methylenedioxyamphetamine (Also
26 known as N-hydroxy MDA);
27 4-methylaminorex;
S.B. No. 172

N-methyl-3-piperidyl benzilate;
Parahexyl (some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenz[ b, d]
pyran; Synhexyl);
1-Phenylcyclohexylamine;
1-Piperidinocyclohexanecarbonitrile (PCC);
[Psilocin,]
[Psilocybin,]
Pyrrolidine Analog of Phencyclidine (some trade
or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);
Tetrahydrocannabinols, other than marihuana, and
synthetic equivalents of the substances contained in the plant, or
in the resinous extractives of Cannabis, or synthetic substances,
derivatives, and their isomers with similar chemical structure and
pharmacological activity such as:
delta-1 cis or trans tetrahydrocannabinol,
and their optical isomers;
delta-6 cis or trans tetrahydrocannabinol,
and their optical isomers;
delta-3, 4 cis or trans
tetrahydrocannabinol, and its optical isomers; or
compounds of these structures, regardless of
numerical designation of atomic positions, since nomenclature of
these substances is not internationally standardized;
Thiophene Analog of Phencyclidine (some trade or
other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl
Analog of Phencyclidine; TPCP, TCP);
1-pyrrolidine (some trade or other name: TCPy);
1-(3-trifluoromethylphenyl)piperazine (trade or other name: TFMPP); and
3,4,5-trimethoxy amphetamine;

(2) Phenylacetone (some trade or other names: Phenyl-2-propanone; P2P, Benzylmethyl ketone, methyl benzyl ketone);

(3) unless specifically excepted or unless listed in another Penalty Group, a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant or stimulant effect on the central nervous system:

Aminorex (some trade or other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5-phenyl-2-oxazolamine);

Amphetamine, its salts, optical isomers, and salts of optical isomers;
Cathinone (some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone);

Etaqualone and its salts;
Etorphine Hydrochloride;
Fenethylline and its salts;
Lisdexamfetamine, including its salts, isomers, and salts of isomers;
Mecloqualone and its salts;
Methaqualone and its salts;
Methcathinone (some trade or other names: 2-methylamino-propiophenone; alpha-(methylamino)propriophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methaminopropriophenone; monomethylpropion; ephedrine, N-methycathinone; methycathinone; AL-464; AL-422; AL-463; and UR 1431);
N-Ethylamphetamine, its salts, optical isomers, and salts of optical isomers; and
N,N-dimethylamphetamine (some trade or other names: N,N,alpha-trimethylbenzeneethanamine [W1][W1][W1][W1][W1]alpha trimethylbenzeneethanamine]; N,N,alpha-trimethylphenethylamine), its salts, optical isomers, and salts of optical isomers; and
(4) any compound structurally derived from 2-aminopropanal by substitution at the 1-position with any monocyclic or fused-polycyclic ring system, including:
(A) compounds further modified by:
(i) substitution in the ring system to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents), whether or not further substituted in the ring system by other substituents;
(ii) substitution at the 3-position with an alkyl substituent; or
(iii) substitution at the 2-amino nitrogen atom with alkyl, benzyl, dialkyl, or methoxybenzyl groups, or inclusion of the 2-amino nitrogen atom in a cyclic structure; and
(B) by example, compounds such as:
S.B. No. 172

1  4-Methylmethcathinone (Also known as
2  Mephedrone);
3  3,4-Dimethylmethcathinone (Also known as
4  3,4-DMMC);
5  3-Fluoromethcathinone (Also Known as 3-FMC);
6  4-Fluoromethcathinone (Also known as
7  Flephedrone);
8  3,4-Methylenedioxy-N-methylcathinone (Also
9  known as Methylene);
10  3,4-Methylenedioxypyrovalerone (Also known
11  as MDPV);
12  alpha-Pyrrolidinopentiophenone (Also known
13  as alpha-PVP);
14  Naphthylpyrovalerone (Also known as
15  Naphyrone);
16  alpha-Methylamino-valerophenone (Also known
17  as Pentedrone);
18  beta-Keto-N-methylbenzodioxolylpropylamine
19  (Also known as Butylene);
20  beta-Keto-N-methylbenzodioxolylpentanamine
21  (Also known as Pentylene);
22  beta-Keto-Ethylbenzodioxolylbutanamine
23  (Also known as Eutylene); and
24  3,4-methylenedioxy-N-ethylcathinone (Also
25  known as Ethylene),
26  (5) any compound structurally derived from tryptamine
27  (3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine:
S.B. No. 172

(A) by modification in any of the following ways:

(i) by substitution at the amine nitrogen atom of the sidechain to any extent with alkyl or alkenyl groups or by inclusion of the amine nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain (alpha-position) with an alkyl or alkenyl group;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy or halide substituents; or

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent; and

(B) including:

(i) ethers and esters of the controlled substances listed in this subdivision; and

(ii) by example, compounds such as:

alpha-ethyltryptamine;
alpha-methyltryptamine;
Bufotenine (some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;
3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; 5-hydroxy-N, N- dimethyltryptamine; mappine);
Diethyltryptamine (some trade and other names: N, N-Diethyltryptamine, DDT);
Dimethyltryptamine (trade or other name: DMT);
S.B. No. 172

5-methoxy-N, N-diisopropyltryptamine

(5-MeO-DiPT);

O-Acetylpsilocin (Trade or other name:

4-Aco-DMT);

Psilocin; and

Psilocybin;

(6) 2,5-Dimethoxyphenethylamine and any compound
structurally derived from 2,5-Dimethoxyphenethylamine by
substitution at the 4-position of the phenyl ring to any extent
(including alkyl, alkoxy, alkenedioxy, haloalkyl, or halide
substituents), including, by example, compounds such as:

4-Bromo-2,5-dimethoxyphenethylamine (trade or
other name: 2C-B);

4-Chloro-2,5-dimethoxyphenethylamine (trade or
other name: 2C-C);

2,5-Dimethoxy-4-methylphenethylamine (trade or
other name: 2C-D);

4-Ethyl-2,5-dimethoxyphenethylamine (trade or
other name: 2C-E);

4-Iodo-2,5-dimethoxyphenethylamine (trade or
other name: 2C-I);

2,5-Dimethoxy-4-nitrophenethylamine (trade or
other name: 2C-N);

2,5-Dimethoxy-4-(n)-propylphenethylamine (trade
or other name: 2C-P);

4-Ethylthio-2,5-dimethoxyphenethylamine (trade
or other name: 2C-T-2);
S.B. No. 172

4-Isopropylthio-2,5-dimethoxyphenethylamine (trade or other name: 2C-T-4); and

2,5-Dimethoxy-4-(n)-propylthiophenethylamine (trade or other name: 2C-T-7); and

(7) 2,5-Dimethoxyamphetamine and any compound structurally derived from 2,5-Dimethoxyamphetamine by substitution at the 4-position of the phenyl ring to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents), including, by example, compounds such as:

4-Ethylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-2);

4-Isopropylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-4);

4-Bromo-2,5-dimethoxyamphetamine (trade or other name: DOB);

4-Chloro-2,5-dimethoxyamphetamine (trade or other name: DOC);

2,5-Dimethoxy-4-ethylamphetamine (trade or other name: DOET);

4-Iodo-2,5-dimethoxyamphetamine (trade or other name: DOI);

2,5-Dimethoxy-4-methylamphetamine (trade or other name: DOM);

2,5-Dimethoxy-4-nitroamphetamine (trade or other name: DON);

4-Isopropyl-2,5-dimethoxyamphetamine (trade or other name: DOIP); and
S.B. No. 172

2,5-Dimethoxy-4-(n)-propylamphetamine (trade or other name: DOPR).

(c) To the extent Subsection (a)(4), (5), (6), or (7) conflicts with another provision or this subtitle or another law, the other provision [subtitle] or the other law prevails. If a substance listed in this section is also listed in another penalty group, the listing in the other penalty group controls.

(d) If a substance listed in this section is approved by the Federal Drug Administration, the inclusion of that substance in this penalty group does not apply, and notwithstanding any other law, a person may not be convicted for the manufacture or delivery of the substance under Section 481.113 or for possession of the substance under Section 481.116.

SECTION 4. The change in law made by this Act applies only to an offense committed on or after the effective date of this Act. An offense committed before the effective date of this Act is governed by the law in effect on the date the offense was committed, and the former law is continued in effect for that purpose. For purposes of this section, an offense was committed before the effective date of this Act if any element of the offense occurred before that date.

SECTION 5. This Act takes effect September 1, 2015.
S.B. No. 172

President of the Senate

I hereby certify that S.B. No. 172 passed the Senate on March 24, 2015, by the following vote: Yeas 31, Nays 0.

Speaker of the House

Secretary of the Senate

I hereby certify that S.B. No. 172 passed the House on May 11, 2015, by the following vote: Yeas 136, Nays 1, one present not voting.

Chief Clerk of the House

Approved:

5-20-2015

Date

Governor

FILED IN THE OFFICE OF THE SECRETARY OF STATE
7:00 O'CLOCK
MAY 22, 2015

Secretary of State
TO: Honorable John Whitmire, Chair, Senate Committee on Criminal Justice

FROM: Ursula Parks, Director, Legislative Budget Board

IN RE: SB172 by Huffman (Relating to the addition of certain substances to Penalty Groups 1-A and 2 of the Texas Controlled Substances Act for criminal prosecution and other purposes.), Committee Report 1st House, Substituted

| No significant fiscal implication to the State is anticipated. |

The bill would amend the Health and Safety Code as it relates to the addition of certain substances to the list of Penalty Group 1-A and Penalty Group 2 substances in the Texas Controlled Substances Act. Under current law, possession of a Penalty Group 1-A and Penalty Group 2 substances are punishable at various felony levels and punishment is based on the amount of substance possessed.

This analysis assumes the Department of Public Safety could implement the provisions of the bill within existing appropriations. This analysis assumes the provisions of the bill would not result in a significant impact on state correctional agencies.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 405 Department of Public Safety
LBB Staff: UP, KJo, LM, ESi, JAW
TO: Honorable John Whitmire, Chair, Senate Committee on Criminal Justice

FROM: Ursula Parks, Director, Legislative Budget Board

IN RE: SB172 by Huffman (Relating to the addition of certain substances to Penalty Groups 1-A and 2 of the Texas Controlled Substances Act for criminal prosecution and other purposes.), As Introduced

Estimated Two-year Net Impact to General Revenue Related Funds for SB172, As Introduced:

a negative impact of ($2,379,000) through the biennium ending August 31, 2017.

General Revenue-Related Funds, Five-Year Impact:

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Probable Net Positive/(Negative) Impact to General Revenue Related Funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>($2,379,000)</td>
</tr>
<tr>
<td>2017</td>
<td>$0</td>
</tr>
<tr>
<td>2018</td>
<td>$0</td>
</tr>
<tr>
<td>2019</td>
<td>$0</td>
</tr>
<tr>
<td>2020</td>
<td>$0</td>
</tr>
</tbody>
</table>

All Funds, Five-Year Impact:

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Probable Savings/(Cost) from General Revenue Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>($2,379,000)</td>
</tr>
<tr>
<td>2017</td>
<td>$0</td>
</tr>
<tr>
<td>2018</td>
<td>$0</td>
</tr>
<tr>
<td>2019</td>
<td>$0</td>
</tr>
<tr>
<td>2020</td>
<td>$0</td>
</tr>
</tbody>
</table>

Fiscal Analysis

The bill would amend the Health and Safety Code as it relates to the addition of certain substances to the list of Penalty Group 1-A and 2 substances in the Texas Controlled Substances Act. Under current law, possession of a Penalty Group 1-A and 2 substances are punishable at various felony levels and punishment is based on the amount of substance possessed.

The Department of Public Safety (DPS) has indicated the bill would require the agency to
purchase new Gas Chromatography Fourier Transform Infrared spectrometers (GS FTIR) necessary for compound identification for each of the thirteen crime laboratories operated by the agency.

Methodology

This analysis assumes the agency would need to acquire new GS FTIR spectrometers for each of the agency's thirteen drug testing laboratories at a cost of $183,000 per unit. Assuming the agency purchases all thirteen of these spectrometers in fiscal year 2016, the one-time cost in fiscal year 2016 is $2,379,000. It is assumed any ongoing costs associated with operating and maintaining this new equipment can be absorbed within the agency's resources.

This analysis assumes the provisions of the bill related to criminal penalties would not result in a significant impact on state correctional agencies.

Technology

The agency has indicated that implementation of this bill will not have a technological impact.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 405 Department of Public Safety
LBB Staff: UP, KJo, AI, ESi, LM, JAW
The bill would amend the Health and Safety Code as it relates to the addition of certain substances to the list of Penalty Group 1-A and Penalty Group 2 substances in the Texas Controlled Substances Act. Under current law, possession, manufacture, delivery, or possession with intent to deliver a Penalty Group 1-A or a Penalty Group 2 substance is punishable at various felony levels and punishment is based on the amount of substance possessed.

Expanding the list of substances for which possession is a criminal offense is expected to result in increased demands upon the correctional resources of the state due to longer terms of probation or longer terms of confinement in state correctional institutions. This analysis assumes the provisions of the bill would not significantly impact state correctional populations, programs, or workloads.
TO: Honorable John Whitmire, Chair, Senate Committee on Criminal Justice

FROM: Ursula Parks, Director, Legislative Budget Board

IN RE: SB172 by Huffman (Relating to the addition of certain substances to Penalty Groups 1-A and 2 of the Texas Controlled Substances Act for criminal prosecution and other purposes.), As Introduced

The bill would amend the Health and Safety Code as it relates to the addition of certain substances to the list of Penalty Group 1-A and Penalty Group 2 substances in the Texas Controlled Substances Act. Under current law, possession, manufacture, delivery, or possession with intent to deliver a Penalty Group 1-A or a Penalty Group 2 substance is punishable at various felony levels and punishment is based on the amount of substance possessed.

Expanding the list of substances for which possession is a criminal offense is expected to result in increased demands upon the correctional resources of the state due to longer terms of probation or longer terms of confinement in state correctional institutions. This analysis assumes the provisions of the bill would not significantly impact state correctional populations, programs, or workloads.

Source Agencies:
LBB Staff: UP, LM, ESi